HAINAN SHUANGCHENG PHARMACEUTICALS CO., LTD. Hainan Shuangcheng Pharmaceuticals Co., Ltd. Share Price
Equities
002693
CNE100001K63
Pharmaceuticals
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.26 CNY | +0.57% |
|
+13.36% | -29.96% |
| Sales 2022 | 275M 37.95M 3.04B | Sales 2023 | 236M 32.59M 2.61B | Capitalization | 3.13B 432M 34.66B |
|---|---|---|---|---|---|
| Net income 2022 | 9M 1.24M 99.7M | Net income 2023 | -50M -6.91M -554M | EV / Sales 2022 | 11.3 x |
| Net Debt 2022 | 77.35M 10.68M 857M | Net Debt 2023 | 113M 15.63M 1.25B | EV / Sales 2023 | 13.7 x |
| P/E ratio 2022 |
364
x | P/E ratio 2023 |
-62.6
x | Employees | 414 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 49.56% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.57% | ||
| 1 week | +13.36% | ||
| Current month | -15.30% | ||
| 1 month | -15.30% | ||
| 3 months | -15.16% | ||
| 6 months | -25.18% | ||
| Current year | -29.96% |
1 week
4.80
5.28
1 month
4.536.28
Current year
3.677.76
1 year
3.679.72
3 years
3.6711.95
5 years
3.4111.95
10 years
3.4121.62
| Managers | Title | Age | Since |
|---|---|---|---|
Jian Ming Li
CEO | Chief Executive Officer | 68 | 30/06/13 |
Xu Guang Wang
DFI | Director of Finance/CFO | 56 | 31/07/05 |
Cheng Dong Wang
CHM | Chairman | 71 | 21/05/00 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Cheng Dong Wang
CHM | Chairman | 71 | 21/05/00 |
Ying Pu Wang
BRD | Director/Board Member | 43 | 31/12/07 |
Jian Lin Yuan
BRD | Director/Board Member | 51 | 31/01/03 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 30/04/24 | 5.26 | +0.57% | 9,041,410 |
| 29/04/24 | 5.23 | +3.77% | 10,120,400 |
| 26/04/24 | 5.04 | +0.40% | 11,733,600 |
| 25/04/24 | 5.02 | +3.08% | 14,795,500 |
| 24/04/24 | 4.87 | +0.83% | 5,931,300 |
End-of-day quote Shenzhen S.E., April 29, 2024
More quotes
Hainan Shuangcheng Pharmaceuticals Co., Ltd. is a China-based company principally engaged in the production, sale, research and development of chemically synthesized peptide drugs. The Company's main products include Jitai (thymalfasin for injection), for the treatment of various types of liver diseases, cancers, geriatric deseases and infectious diseases; thymopentin for infection; somatostatin, for the treatment of severe acute esophageal variceal bleeding and severe acute stomach or for the adjuvant therapy of duodenal ulcer bleeding and diabetic ketoacidosis, as well as other drugs. The Company distributes its products in domestic market and to overseas markets.
Sector
Pharmaceuticals
Calendar
28/08/2024
- Q2 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -29.96% | 303M | |
| +19.27% | 43.18B | |
| +22.12% | 23.23B | |
| +15.11% | 14.6B | |
| +38.36% | 11.5B | |
| -7.91% | 6.79B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +10.21% | 5.31B | |
| -2.27% | 4.81B |
- Stock Market
- Equities
- 002693 Stock
